Gliflozins, a class of medications, belong to the family of sodium-glucose cotransporter 2 (SGLT2) inhibitors. These pharmaceutical agents are designed to treat type 2 diabetes by targeting a key mechanism in glucose regulation. The primary action of gliflozins occurs in the kidneys, where they inhibit SGLT2, a protein responsible for reabsorbing glucose from the urine back into the bloodstream. By blocking this reabsorption, gliflozins promote the excretion of excess glucose through urine. This unique mechanism of action makes gliflozins an innovative approach to managing diabetes. By increasing urinary glucose excretion, they help lower blood glucose levels and contribute to improved glycemic control. Additionally, gliflozins may lead to modest weight loss and have been associated with cardiovascular benefits in some patients. Common members of the gliflozin class include dapagliflozin, empagliflozin, and canagliflozin. These medications are typically prescribed as part of a comprehensive diabetes management plan, often in combination with other antidiabetic drugs. It's important to note that, like any medication, gliflozins are not without potential side effects, and their use should be guided by healthcare professionals based on individual patient characteristics and needs. Overall, gliflozins represent an important advancement in the treatment of type 2 diabetes, offering a novel therapeutic avenue to help patients achieve better glucose control.